Last reviewed · How we verify
Placebo-rituximab
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | Placebo-rituximab |
|---|---|
| Also known as | nacl |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their destruction through mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This results in a reduction in B cell count and activity, which can be beneficial in treating certain autoimmune and malignant conditions.
Approved indications
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Infusion-related reactions
- Infections
- Neutropenia
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Iptacopan in Patients With ANCA Associated Vasculitis (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis (PHASE2)
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma (PHASE3)
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (PHASE3)
- Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) (PHASE2)
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-rituximab CI brief — competitive landscape report
- Placebo-rituximab updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI